Check out today's blog post with updates about ASCO from our Science and Research Team
Here is the link: go2foundation.org/blog/what...
Check out today's blog post with updates about ASCO from our Science and Research Team
Here is the link: go2foundation.org/blog/what...
“The results showed that taking Tagrisso (osimertinib) as an additional therapy (known as an “adjuvant” therapy) after surgery and sometimes chemotherapy made a significant difference in the percentage of patients who had a recurrence. After 2 years, 89% of patients on Tagrisso were lung cancer-free vs. 53% of those not taking it.”
Sending hope that this game changer gets approved soon!